- Conditions
- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
- Interventions
- Ponatinib, Chemotherapy Agents
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 187
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Childhood Cancer
- Interventions
- JUMP
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Lumbar Puncture, Mercaptopurine, Methotrexate, Positron Emission Tomography, Rituximab, Vincristine Sulfate
- Drug · Procedure · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Duarte, California • Irvine, California + 5 more
- Conditions
- Leukemia, Pediatric Cancer
- Interventions
- Epratuzumab, Fludarabine, Cyclophosphamide, Mesna, Infusion of NK cells, Interleukin-2
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 9 Years to 16 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate, Multigated Acquisition Scan, Ruxolitinib Phosphate, Tacrolimus
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 2 Years to 22 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- Daratumumab, Vincristine, Prednisone, Doxorubicin, Peg-asparaginase, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate
- Drug · Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 22 more
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event
- Interventions
- Not listed
- Lead sponsor
- Cipherome, Inc.
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy, Methotrexate and Cytarabine
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- B Cell Leukemia
- Interventions
- Autologous CD19 CAR+ EGFTt + T cells
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Lymphomas, Bone Marrow Failure, Hemoglobinopathy, Immune Deficiency, Osteopetrosis, Cytopenias, Leukocyte Disorders, Anemia Due to Intrinsic Red Cell Abnormality
- Interventions
- CD34+ enriched, T Cell Depleted donor stem cell product
- Biological
- Lead sponsor
- Christopher Dvorak
- Other
- Eligibility
- 2 Months to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Leukemia, Lymphoblastic, Acute, ALL, Childhood
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 40 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- Interventions
- AUTO1
- Biological
- Lead sponsor
- Autolus Limited
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Chicago, Illinois • Cincinnati, Ohio + 3 more
- Conditions
- Acute Leukemia, Myelodysplastic Syndrome
- Interventions
- QUAIL-100
- Biological
- Lead sponsor
- Laguna Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Months to 39 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- CareMeds Intervention, Usual Care Group
- Behavioral
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 3 Years to 9 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Leukemia
- Interventions
- Daunorubicin, Vincristine, Prednisone, PEG-Asparaginase, Methotrexate, 6-MP (6-Mercaptopurine), Cyclophosphamide, Cytarabine, Leucovorin, Dexamethasone, Blood draw, CT/PET scans
- Drug · Other · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Durham, North Carolina
- Conditions
- Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
- Interventions
- EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
- Conditions
- Leukemia
- Interventions
- etoposide, mitoxantrone hydrochloride, valspodar
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 50
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 39 more
- Conditions
- Pediatric ALL, Concussion, Mild, Concussion, Brain, Concussion, Intermediate
- Interventions
- Active Rehabilitation Group/Case
- Behavioral
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis), Chronic Myeloid Leukemia - Accelerated Phase
- Interventions
- Orca-Q
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • Miami, Florida • St. Petersburg, Florida
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
- Interventions
- Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Leukemia, Pediatric
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
- Interventions
- AC220, Cytarabine, Etoposide, Methotrexate
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Madera, California • San Francisco, California + 8 more
- Conditions
- Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma
- Interventions
- Venetoclax, Navitoclax
- Drug
- Lead sponsor
- Kathleen Ludwig
- Other
- Eligibility
- 4 Years and older
- U.S. locations
- 1
- States / cities
- Dallas, Texas